Degrader-antibody conjugate (DAC) is a new modality that combines a degrader as payload with a monoclonal antibody to specifically target a particular protein, with a chemical linker to connect. Our company has a large number of candidates in our proprietary degrader library that are suitable for using as DAC payloads. Compared with the last generation of ADC, it is highly tissue-selective and tumor-selective, is not limited by the expression of the target of the antibody, and has a pharmacological feature of catalytic cycling, which greatly improves the therapeutic index.

DAC Advances a New Class of Drug Development

DAC precisely recognizes tumor cells and releases active protein degrader into tumor cells

DAC provides a promising therapeutic index by improving payload efficacy and tissue-specific cytotoxicity

Tumor-specific and Modulation-driven DAC therapeutics

Activity of Validated DAC Payload